Merhi Y, Arsenault A, Carrier M, Latour J G
Laboratory of Experimental Pathology, Montreal Heart Institute, Quebec, Canada.
Cardiovasc Res. 1993 Aug;27(8):1504-9. doi: 10.1093/cvr/27.8.1504.
The aim was to investigate the ability of 111In-antimyosin monoclonal antibody (111In-AMA) to differentiate between salvaged and necrotic myocardium following reperfusion.
Dogs submitted to a 24 h left anterior descending coronary artery occlusion (group 1, n = 10) or to a 90 min occlusion followed by a 22.5 h reperfusion (group 2, n = 11, group 3, n = 5) were given radiolabelled microspheres and 111In-AMA after 75 min of ischaemia (groups 1 and 2), or after 19.5 h of reperfusion (group 3). After delimiting the area at risk and the infarct by dye perfusion and triphenyltetrazolium chloride, the heart slices were imaged by scintigraphy and dissected into necrotic, viable ischaemic, and normal myocardium. Myocardial blood flow was estimated by microspheres and 111In-AMA uptake was expressed as the ratio of the corresponding non-ischaemic tissue samples taken from opposite ventricular wall.
111In-AMA ratios in necrotic and salvaged myocardium were respectively 5.4(SEM 1.9) and 3.2(0.5) times the normal value, giving a 1.7 to 1 factor between the two areas in dogs with permanent occlusion (group 1). Similar results were obtained in group 3 with ratios of 6.1(1.1) and 3.0(0.3) times normal values. In contrast, ratios of 43.6(5.6) and 5.6(0.9) (p < 0.05) in necrotic and salvaged myocardium, respectively, were found in reperfused group 2, giving a 7.8 to 1 factor between the two tissue areas of the risk territory. Clear delineation between salvaged and necrotic tissue territories could be made on scintigrams only in group 2, which otherwise presented smaller infarcts: 35.1(7.9)% of the risk area v 58.0(8.7)% in non-reperfused animals (p < 0.05). 111In-AMA uptake by necrotic myocardium did not correlate with collateral (group 1) or reperfusion blood flows (group 3), indicating that the greater uptake in reperfused myocardium is flow independent.
111In-AMA does not clearly identify necrotic from viable ischaemic myocardium within 24 h of injection in a coronary artery occlusion model. Thus it may not be a sensitive enough method to evaluate infarct size progression. However, reperfusion greatly increased 111In-AMA uptake by the infarct in a flow independent manner, this may prove to be useful for clinical assessment of infarct size and reperfusion injury.
研究铟 - 111标记的抗肌凝蛋白单克隆抗体(111In - AMA)在再灌注后区分存活心肌和坏死心肌的能力。
将犬分为三组,第一组(n = 10)左冠状动脉前降支闭塞24小时;第二组(n = 11)闭塞90分钟后再灌注22.5小时;第三组(n = 5)闭塞90分钟后再灌注19.5小时。在缺血75分钟后(第一组和第二组)或再灌注19.5小时后(第三组)给犬注射放射性微球和111In - AMA。通过染料灌注和氯化三苯基四氮唑确定危险区和梗死区后,对心脏切片进行闪烁显像,并将其解剖为坏死、存活缺血和正常心肌。用微球估计心肌血流量,111In - AMA摄取量表示为取自对侧心室壁相应非缺血组织样本的比值。
在永久性闭塞的犬(第一组)中,坏死心肌和存活心肌的111In - AMA比值分别为正常值的5.4(标准误1.9)倍和3.2(0.5)倍,两个区域之间的比值为1.7比1。第三组也得到类似结果,比值分别为正常值的6.1(1.1)倍和3.0(0.3)倍。相比之下,再灌注的第二组坏死心肌和存活心肌的比值分别为43.6(5.6)和5.6(0.9)(p < 0.05),危险区内两个组织区域之间的比值为7.8比1。仅在第二组的闪烁显像图上能清晰区分存活和坏死组织区域,而且第二组梗死面积较小:为危险区的35.1(7.9)%,而非再灌注动物为58.0(8.7)%(p < 0.05)。坏死心肌对111In - AMA的摄取与侧支循环(第一组)或再灌注血流量(第三组)无关,表明再灌注心肌摄取增加与血流无关。
在冠状动脉闭塞模型中,注射111In - AMA后24小时内,不能清晰区分坏死心肌和存活缺血心肌。因此,它可能不是评估梗死面积进展的足够敏感的方法。然而,再灌注以与血流无关的方式极大地增加了梗死心肌对111In - AMA的摄取,这可能对梗死面积和再灌注损伤的临床评估有用。